- Home
- ALX vs KURA Comparison
ALX vs KURA Comparison
Compare ALX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | KURA |
|---|---|---|
| Founded | 1928 | 2014 |
| Country | United States | United States |
| Employees | N/A | 260 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALX | KURA |
|---|---|---|
| Price | $265.03 | $11.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 19.2K | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 31.15 | N/A |
| Revenue | ★ $213,183,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $201.28 | $7.36 |
| 52 Week High | $289.43 | $12.90 |
Technical Indicators
Market Signals| Indicator | ALX | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 63.99 |
| Support Level | $252.20 | $7.71 |
| Resistance Level | $271.02 | $12.34 |
| Average True Range (ATR) | 6.66 | 0.59 |
| MACD | -0.42 | 0.29 |
| Stochastic Oscillator | 29.45 | 74.14 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.